Dr. Falk Video report
Examination of the kidneys:
Right kidney
Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.
©2019 Falk Foundation e.V., Freiburg. All rights reserved.
Please switch on your loudspeakers!
Link to Falk Mediacenter
Latest research in brief:
Bowel
Text:
Wintzell V et al, Lancet Gastroenterol Hepatol. 2019;4(11):845–53
Risk of serious infections in pediatric inflammatory bowel disease patients: A nationwide cohort study from Denmark indicates that therapy with TNF inhibitors is not associated with increased risk of serious infections requiring hospitalizations.
Link to text
Text:
Kopetz S et al, N Engl J Med. 2019;381(17):1632–43
BRAF inhibition in colorectal cancer: A combination therapy of the BRAF inhibitors encorafenib and binimetinib plus cetuximab results in significantly longer overall survival and a higher response rate than standard therapy in patients with BRAF V600E-mutated metastatic colorectal cancer.
Link to text
Text:
Siegel RL et al,Gut. 2019;68(12):2179–85
Incidence of colorectal cancer in younger adults: Global analysis of colorectal cancer epidemiology indicates that tumor incidence increased in 9 high-income countries spanning 3 continents.
Link to text
Liver Biliary Tracts
Text:
Allen AM et al, J Hepatol. 2019;71(6):1229–36
Cancer risk and non-alcoholic fatty liver disease (NAFLD): A current longitudinal cohort study demonstrates that NAFLD, but not obesity alone, is associated with an increased cancer risk, particularity of gastrointestinal types. These data suggest that NAFLD may be a mediator of the obesity-cancer association.
Link to text
Text:
Harrison SA et al, Lancet. 2019;394(10213):2012–24
Novel therapeutic strategy in non-alcoholic steatohepatitis (NASH): Resmetirom is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. Indeed, a current phase 2 trial demonstrates substantial reduction of hepatic fat after 12 and 36 weeks of treatment with resmetirom.
Link to text
Text:
Honda A et al, Hepatology. 2019;70(6):2035–46
Primary biliary cholangitis (PBC): A retrospective cohort study indicates that the addition of bezafibrate to ursodeoxycholic acid monotherapy improves not only GLOBE and UK-PBC scores but also the long-term prognosis. Of note, this benefit is most prominent in those patients with early-stage PBC.
Link to text
Oesophagus Stomach Duodenum
Text:
Kato K et al, Lancet Oncol. 2019;20(11):1506–17
Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy: Results of a phase 3 trial indicate that nivolumab is associated with a significant improvement in overall survival and a favorable safety profile as compared to chemotherapy with paclitaxel or docetaxel.
Link to text
Text:
Mullee A et al, JAMA Intern Med. 2019;179(11):1479–90
Soft drink consumption and mortality: A large European cohort study found that consumption of sugar-sweetened and artificially sweetened soft drinks is positively associated with all-cause mortality.
Link to text
Text:
Hadjivassiliou M et al, Clin Gastroenterol Hepatol. 2019;17(13):2678–86.e2
Neurologic deficits in patients with newly diagnosed celiac disease: Neurologic deficits were common in a prospective cohort study of patients with a new diagnosis of celiac disease and were associated with antibodies directed against transglutaminase 6. Presence of these antibodies was linked with atrophy of specific brain regions.
Link to text
Pancreas
Text:
GBD 2017 Pancreatic Cancer Collaborators, Lancet Gastroenterol Hepatol. 2019;4(12):934–47
Pancreatic cancer: Globally, the numbers of deaths and incident cases have more than doubled between 1990 and 2017 and will increase further. Development of screening programs and preventive strategies to control risk factors such as smoking, high plasma glucose as well as high body mass index are urgently needed.
Link to text
International Symposia and Workshops
Workshop
Primary Liver Cancer – Emerging Concepts and Novel Treatments
February 13–14, 2020, Mainz, Germany
Philosophicum, Johannes Gutenberg-Universität, Jakob-Welder-Weg 18, 55128 Mainz, Germany
Registration
Online registration
Symposium 218
Current Challenges of Inflammatory Bowel Disease
6.–7. März, 2020, Mexico City, Mexico
Hyatt Regency Hotel, Campos Elíseos 204, Polanco Chapultepec, 11560 Mexico City, Mexico
Registration
Online registration
Current Falk literature:
no literature